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ABSTRACT 
Objective 
We aimed to determine whether nosocomial SARS-CoV-2 infection has worse 
outcomes than community-acquired disease and to identify demographic, 
biochemical and investigational predictors for severe disease. 
Design 
Prospective cohort study.  Patients were followed up for at least 30 days. 
Setting 
Three acute hospitals in a single NHS trust. 
Patients 
All hospitalised patients with confirmed COVID-19 on 9th April 2020. 
Methods 
Nosocomial infection was defined as positive swab after 7 days of admission.  
Baseline characteristics, investigation findings and patient level of care were 
analysed.  We explored whether these variables were predictive of poor outcomes 
including increased length of stay (LOS), critical care admission, and death. 
Results 
173 patients were identified, 19 (11.0%) had nosocomial infection.  32 (18.5%) had 
30-day all-cause mortality; there was no statistically significant differences between 
30-day mortality rates between nosocomial infection and those admitted due to, or 
incidentally with SARS-CoV-2 infection (21.1% vs 17.6% vs 21.6% respectively, 
p=0.755).  Admission blood profile and chest X-ray findings were also not predictive 
of mortality.  The age-adjusted Charlson comorbidity index (ACCI), Scottish Index of 
Multiple Deprivation (SMID) and admission to critical care were all significant 
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predictors of LOS (p<0.05).  In patients who did not attend critical care, male 
(HR=3.36, p<0.05) and high ACCI (HR=1.29, p<0.05) were predictors of mortality.    
Conclusions 
Nosocomial SARS-CoV-2 infection is not associated with increased mortality 
compared with community acquired infection.  ACCI score and male sex are 
predictors of poor outcomes.  SMID is a predictor of LOS but not mortality.  
Keywords 
SARS-CoV-2, pandemic, socioeconomic deprivation, 30-day mortality, co-
morbidities, outcomes. 
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INTRODUCTION 
In December 2019 a series of viral pneumonia cases were reported in Wuhan, Hubei 
province, China.  The World Health Organization (WHO) named the novel 
coronavirus SARS-CoV-2 as the causative virus of the disease COVID-19.  On 30 
January 2020, the WHO declared that this viral outbreak constituted a Public Health 
Emergency of International Concern.  The spectrum of disease severity is wide, 
generally around 81% of cases are mild, 14% severe and 5% critical, with outcomes 
influenced by a range of factors.1  No vaccine is available and the mainstay of 
treatment for COVID-19 is supportive.2 
 
All age groups are susceptible, but elderly patients are more likely to have severe 
disease.1 Co-morbidities that increase mortality have been well described in recent 
literature. The Age-adjusted Charlson co-morbidity index (ACCI) is a widely used 
prognostic indicator that assesses risk conferred by age and co-morbid disease and 
allows a more pragmatic approach to comparisons within populations. The Scottish 
Index of Multiple Deprivation (SIMD) is a relative measure of 7 domains (income, 
employment, education, health, access to services, crime and housing) used to 
target policies and funding to more deprived areas.  
Whilst the median incubation period of SARS-CoV-2  infection is around 4 days 
(range 1-14 days), patients can be contagious before the onset of symptoms and the 
duration of infectivity remains uncertain.2  
Our primary aim was to determine whether nosocomial SARS-CoV-2 infections 
increased mortality rates compared with community-acquired disease after adjusting 
for covariates.  Our secondary aim was to identify demographic and other risk factors 
for severe SARS-CoV-2 infection outcomes. 
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METHODS 
Study Design and Participants  
A prospective cohort study was conducted on all hospitalized patients with reverse 
transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infection, 
on a single day.  This was carried out across three acute hospitals in a single 
National Health Service (NHS) Trust in Scotland serving a population of 655,000.  
 
Data collection 
Patients with positive RT-PCR swabs were identified from TrakCare Electronic 
Medical Record System.  Demographic data, SIMD score and ACCI were extracted 
from electronic case records.   
 
Patients were categorised into three distinct groups based on the reason of 
admission: group 1 were admitted with suspicion of SARS-CoV-2 infection, group 2 
presented with other pathologies but were incidentally found to have SARS-CoV-2 
infection on admission (or within 7 days of admission), and group 3 were admitted 
with other pathologies and contracted COVID-19 infection in hospital (positive RT-
PCR after 7 days of admission).  In patients with nosocomial SARS-CoV-2 infection, 
day 0 was defined as the date of positive RT-PCR.  All patients were included in the 
study and followed up for 30 days from admission or until discharge or death. 
 
Outcome measures  
We defined a poor outcome as including all cause 30-day mortality and/or need for 
critical care admission.  Baseline characteristics were compared between 
survivors/non-survivors.  
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Statistical analyses 
Length of stay (LOS) was calculated from the date of positive COVID-19 diagnosis 
until discharge or death.  Covariates controlled for included ACCI, sex, deprivation 
decile and transfer to critical care.  Age was not included as this is included in the 
ACCI. 
Multivariate logistic regression was performed to explore predictors of transfer to 
critical care.  Only group 1 was included in this analysis due to a lack of data in 
groups 2 and 3.  Covariates included in this analysis were ACCI, sex and deprivation 
decile.  ACCI was categorised as either a low (ACCI = 0-3) or high (ACCI = 4+). 
A p value of <0.05 was considered statistically significant.   
 
This study was registered with the NHS Lanarkshire’s Clinical Quality Project, project 
ID: 13124. 
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RESULTS 
We identified 173 patients of whom 108 (62.4%) were male, with a mean (SD) age of 
68 (14.7) years.  Of these, 31 (17.9 %) died within 30-days of positive RT-PCR.  
Median time to acquire nosocomial COVID-19 infection was 35 days (IQR = 18, 42).  
Summary baseline patient characteristics for each admission group were calculated 
and differences explored with univariate analyses (table I).  There was no significant 
difference in mortality between the groups.  Figure I shows a Kaplan-Meier plot of 
Groups 1, 2 and 3 (unadjusted). 
 
Length of stay 
Data on length of stay is reported only for those patients primarily admitted for 
treatment of COVID or who had incidental COVID on admission (groups 1 and 2). 
Admission type was not a predictor of LOS, although ACCI (p<0.001), admission to 
critical care (p<0.001) and deprivation decile (p<0.05) were all significant predictors 
of LOS.  Beta estimates and confidence intervals for each covariate can be found in 
the additional file. 
 
Critical care admission 
The overall model was significant (ぬ2=22.98, df = 3, p<0.001) and 70.0% accurate.  
Of the included covariates, only ACCI was significant (OR=0.114, p<0.001) 
suggesting that patients with a higher ACCI were less likely to be admitted to critical 
care (additional file). 
 
Survival analysis  
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Analysis of 30-day mortality was stratified by critical care admission.  Out of 125 
patients not attending critical care, there were 19 deaths within 30 days.  For this 
cohort, a Cox’s PH model showed both ACCI (HR=1.29, p<0.05) and male sex 
(HR=3.36, p<0.05) were predictive of 30-day mortality.  Neither admission status nor 
deprivation decile were found to be significant.  Among 48 patients who attended 
critical care, there were 13 deaths within 30 days of diagnosis.  Neither ACCI nor sex 
were significant predictors of mortality in this group.  The small sample size, 
however, means results from this model should be interpreted with caution.  Survival 
curves for these groups are available in the additional file. 
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DISCUSSION  
Patients in our hospital-based population had a 30-day mortality rate of 18.5%.  Our 
study shows that male sex and ACCI score were predictive factors for 30-day 
mortality in those not attending critical care.  We also found SMID and ACCI scores 
to be predictive of LOS. 
Importantly we have shown that nosocomial COVID-19 is not associated with 
increased mortality after adjusting for ACCI score.  This is likely to be reflective of 
other parts of the UK.  There have been over 15,000 positive cases to date (end May 
2020) in Scotland with approximately a 15% (versus our 18.5%) case fatality rate.3  
This lower figure is likely representative of the increased acuity of hospitalised 
patients compared with the national population. 
 
Male sex was associated with poor outcomes as seen in previous studies,2 no 
patients with an ACCI score of ≤1 died, yet those with a score 2 had a greater than 
25% chance of mortality.  The median ACCI score in this study was 4 equating to an 
estimated 53% 10-year survival representing a very high comorbid disease burden in 
our study population.  Similar results have been reported where the incidence of co-
morbidities was higher in COVID-19 patients than the general age-matched 
population.7 Our finding that patients with a higher ACCI score were less likely to be 
admitted to critical care is expected as they may be less likely to be accepted for ITU 
admission due to the perceived high chance of non-survival.  Interestingly, male sex 
was a predictor of mortality only in those patients who were not admitted to critical 
care. 
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Recent unpublished statistical modelling performed by Public Health England (PHE) 
predicts approximately 20% of hospital inpatient SARS-CoV-2 infections are 
nosocomial.8 Only 11% of cases in our study were nosocomial, and stringent 
isolation practices already implemented may explain these low relatively low results.  
Furthermore, our hospitals were not fully saturated with COVID-19 during the 
pandemic, and during our study only 55% of beds were occupied (excluding critical 
care).  This may in part explain lower COVID-19 nosocomial infection rates than 
predicted by PHE. 
 
In our study, there was a 21.1% 30-day mortality rate among patients with 
nosocomial infection compared to 17.6% in those presenting with COVID-19, though 
our analysis does not suggest that this is statistically significant.  However, our 
sample size was small, and results should be interpreted with caution. Compared 
with patients admitted with symptomatic SARS-CoV-2 infection, patients with 
nosocomial infection were significantly older and had higher ACCI scores. This 
indicates an ongoing risk for vulnerable patient groups such as has been 
demonstrated by care homes across the UK.  
One of the greatest challenges with COVID-19 infection is that it can present with a 
wide spectrum of illness, including symptoms similar to those of common respiratory 
viruses, or may be entirely asymptomatic, increasing risks of nosocomial infection. 
This presents challenges for availability of isolation and containment rooms in busy 
hospitals, and many patients admitted without suspicious contact history or 
characteristic presenting symptoms of COVID-19 may receive care outside 
dedicated isolation areas. 
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The initial cross-sectional method of participant identification in this study enables a 
valid representation of the hospital population in this health board and data was 
collected across all departments.  However, this method will be subject to a degree 
of length-time bias as patients with longer hospital stays would be more likely to be 
picked up by this method of identification leading to inaccurate measures of survival / 
discharge.  
A key limitation to this study is the small sample size. Our group sizes were not 
equal, we only recruited 19 nosocomial infections for analysis, which made it difficult 
to confidently analyse differences. Collecting data in more than one region and 
recruiting a greater sample size with a control population, would improve the validity 
and generalisability of the data. 
There is currently no WHO approved definition for nosocomial infection.  A cut off as 
4 days after initial hospitalisation and the absence of clinical suspicion of COVID-19 
has been utilised previously.9  As the incubation period could be up to 14 (IQR 2-7) 
days, it is difficult to be certain that an infection was acquired in hospital. 2  
Nosocomial infections may be less advanced when they are detected due the 
heightened awareness of COVID-19 symptoms by healthcare workers.  This means 
we may identify more mild cases in group 3 in comparison to those requiring hospital 
admission in groups 1 and 2. Conversely, at the time of data collection, only patients 
who were symptomatic were tested in hospital, meaning there may have been a 
greater number of asymptomatic nosocomial infections who would’ve been included 
in Group 3.  Patients in groups 1 and 2 may have different thresholds for self-
presentation to hospital.  This means our defined day 0 may vary between patients.  
We did not include group 3 in our length of stay analysis as by definition they had 
 Outcomes in nosocomial SARS-CoV-2 infection 
 
14 | P a g e  
 
already been admitted to hospital for a minimum of 7 days for other pathologies 
making LOS comparison with those admitted with SARS-CoV-2 infection impossible. 
 
Our study demonstrates that nosocomial SARS-CoV-2 infection is not associated 
with a statistically significant increase in 30-day mortality compared with community 
acquired infection.  Male sex, age and ACCI score are significant predictors of 
mortality in the whole cohort.  A high degree of vigilance will be required by all 
members of the healthcare team to prevent the spread of SARS-CoV-2 within 
hospitals.  Nosocomial infection poses an important challenge to vulnerable hospital 
populations, and needs to be considered as the NHS attempts to resume elective 
activities, balancing the risks and benefits whilst the COVID-19 pandemic continues.  
Our study shows a relatively low risk of contracting COVID-19 infection in hospital 
with comparable outcomes to when the disease was contracted in the community.  
Further studies are essential to identify the mechanisms and to gain a greater 
understanding of how certain risk factors influence outcomes with COVID-19 disease 
in order to guide public health initiatives aimed to shield at risk groups and save 
lives. 
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Table I –Baseline characteristics and main outcomes: Analyses performed 
included one-way ANOVA (age), Fisher’s Exact Tests (sex, ITU attendance, 
death) and Kruskal-Wallis tests (ACCI, deprivation decile). 
 Total Group 1 Group 2 Group 3 P 
value 
Total patients 173 131 23 19 NA 
Mean age (SD) 68.44 
(14.7) 
66.14 
(13.8) 
78.39 
(10.0) 
72.26 
(19.3) 
<0.001 
Male (%) 108 
(62.4) 
90 (68.7) 9 (39.1) 9 (47.4) <0.01 
Median ACCI (IQR) 4 (2, 6) 3 (2, 5) 6 (4.5, 7) 5 (4, 7) <0.001 
Median deprivation 
decile (IQR) 
4 (2, 6) 5 (2, 7) 3 (2, 5) 4 (3, 5.5) 0.321 
Attended critical care 
(%) 
48  (27.7) 45 (34.4) 1 (4.3) 2 (10.5) <0.01 
30-day mortality 32 (18.5) 23 (17.6) 5 (21.7) 4 (21.1) 0.755 
ITU = Intensive Treatment Unit, ACCI = Age-adjusted Charlson Co-morbidity 
Index, SD= Standard Deviation, IQR = Interquartile Range.  
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FIGURE LEGENDS 
 
Figure 1 - Kaplan-Meier plot stratified by admission group (Group 1 = admitted for 
SARS-CoV-2 infection, group 2 = incidental Sars-Cov-2 infection, group 3 = 
nosocomial Sars-Cov-2 infection). 
 
 
